Biotech IV Monitor

BIIB — Biogen Inc.

$32.7B market cap · 8 upcoming readouts tracked

Clinical trial readout dates for Biogen Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts86 Phase 3
Market cap$32.7B
Recent 8-K filings1latest 2026-10-28

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 Nusinersen
Muscular Atrophy, Spinal · NCT04729907
July 2026
Primary data collected

Upcoming readouts

Phase 3 Felzartamab
Antibody-mediated Rejection · NCT06685757
December 2026
Ongoing
Phase 3 BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting · NCT03958877
May 2027
Ongoing
Phase 3 Felzartamab
Immunoglobulin A Nephropathy (IgAN) · NCT06935357
May 2027
Recruiting
Phase 3 Tofersen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation · NCT04856982
August 2027
Ongoing
Phase 3 Nusinersen
Spinal Muscular Atrophy · NCT05067790
September 2027
Ongoing
Phase 3 Omaveloxolone
Friedreich Ataxia · NCT06953583
November 2027
Ongoing
Phase 2 Felzartamab
Graves' Disease · NCT07722546
January 2028
Recruiting
Phase 2 Felzartamab
Microvascular Inflammation · NCT07219043
February 2028
Recruiting

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-28

Companies working on similar indications

Discussion

No messages yet. If you follow BIIB, you can start the conversation.
Track BIIB in real time
See live implied volatility for BIIB and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on BIIB
Contact — questions or corrections about BIIB: dukeupt@gmail.com